
Pfizer recall two batches of migraine drug Relpax
pharmafile | August 16, 2019 | News story | Medical Communications | FDA, Pfizer, Relpax, migraine, pharma, recall
Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination.
In a statement on the FDA website, Pfizer said: “Individuals who consume oral products contaminated with microorganisms are at risk of bacterial dissemination from the gut to the bloodstream potentially resulting in serious, life- threatening infections.”
However the firm said the risk of infection was low for the general population. The risk may be higher for those with compromised immune systems, cystic fibrosis and chronic granulomatous disease.
The two lots of 40mg tablets are labelled AR5407 and CD4565. Pfizer has not yet received any complaints or reports of adverse events relating to the batches.
Louis Goss
Related Content

One in three UK women with migraine say symptoms taken less seriously
One in three UK women who have experienced migraine say they believe their symptoms are …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …





